Can You Buy B7-33 Peptide? What Patients Should Know

B7-33 is a synthetic relaxin-family peptide studied mainly in preclinical research for RXFP1 signaling, fibrosis biology, and vascular effects. It is not listed as a treatment Chia offers, and patient use should not be assumed from lab or animal findings. If you are seeking peptide therapy, use a licensed clinician-reviewed path rather than research-only sellers.

Can you buy B7-33 peptide for personal use?

B7-33 peptide can be found on some research-supplier websites, but that is not the same as a prescription treatment. Research listings do not establish that a product is appropriate, sterile, correctly identified, or safe for human use.

Direct answer for patients

Chia does not offer B7-33. We would not treat a research-only listing as proof that a peptide is suitable for self-injection or personal use.

B7-33 was developed as a smaller relaxin-family peptide that targets relaxin family peptide receptor 1, also called RXFP1, in research systems 1. The main human-use gap is simple: published studies do not establish a validated human dosing regimen, confirmed clinical benefit, or full safety profile for patients.

Why research peptide listings are different from prescription treatment

A research peptide may be sold for laboratory use, not as medication. FDA guidance warns that drugs bought from unsafe online sources may contain the wrong ingredient, too much or too little active ingredient, harmful contaminants, or unsafe packaging and storage conditions 6.

What to verify before trusting any peptide seller

• Is a licensed clinician reviewing your medical history, medications, contraindications, and goals?
• Is the product being dispensed by a state-licensed pharmacy when prescribed for human use?
• Is there a clear plan for side effects, lab monitoring when needed, and follow-up?
• Is the seller making treatment claims that go beyond human evidence?
• Is the product labeled for research use only, not for human use, or laboratory use only?

What is B7-33 peptide?

B7-33 is a synthetic peptide related to human relaxin-2, also called H2-relaxin. Researchers designed it to keep selected RXFP1 activity while using a smaller, single-chain structure than native relaxin peptides 1.

How B7-33 relates to H2-relaxin and serelaxin

Human relaxin-2 is a natural hormone in the relaxin peptide family. Serelaxin is a recombinant form of human relaxin-2 that has been studied in acute heart failure trials, including RELAX-AHF and RELAX-AHF-2 4, 5.

B7-33 is different. It is a simplified relaxin-family derivative studied to understand whether some relaxin-like effects can be separated from other signaling pathways 1. That research idea is interesting, but it does not make B7-33 a proven patient therapy.

What RXFP1 means

RXFP1 stands for relaxin family peptide receptor 1. It is one receptor that relaxin-family peptides can activate; RXFP2 is a related receptor with different biology 1.

Why researchers created smaller relaxin derivatives

Large peptide hormones can be hard to manufacture, stabilize, and deliver. B7-33-related research has focused on making smaller derivatives with improved potency, stability, or drug-like properties, which shows active development rather than established clinical use 2.

What does B7-33 peptide do in research studies?

B7-33 research centers on RXFP1 signaling, ERK1/2 activation, collagen turnover, MMP-2, and vascular function. These findings are mostly mechanistic and preclinical, so they should not be read as proven human outcomes.

RXFP1 signaling and functional selectivity

In the original B7-33 research, investigators described it as a functionally selective RXFP1 agonist 1. In plain English, that means B7-33 may activate some receptor signals more than others, rather than copying every effect of native relaxin.

ERK1/2 signaling versus cAMP signaling

The B7-33 literature discusses ERK1/2-related signaling, including pERK pathway activity, with less emphasis on cAMP signaling than full relaxin-family agonism 1, 2. That signaling pattern is one reason researchers study B7-33 as a tool compound.

MMP-2, collagen turnover, and fibrosis research

B7-33 has been studied for anti-fibrotic mechanisms involving matrix metalloproteinase-2, or MMP-2, and collagen turnover 1. Fibrosis means excess scar-like tissue buildup; changing a fibrosis marker in a model is not the same as proving that a peptide improves a human disease.

Vascular and endothelial-function research

B7-33 has also been studied in vascular-function models. In a 2017 European Journal of Pharmacology study, Marshall and colleagues reported that B7-33 replicated several vasoprotective functions of human relaxin-2, also called serelaxin, in experimental systems 3.

Is there human clinical evidence for B7-33?

B7-33 does not have the kind of human clinical evidence patients should expect before using a peptide as treatment. The supplied research supports cell, tissue, and animal biology, not a proven human safety or benefit profile.

What the supplied research can and cannot show

The B7-33 papers help explain receptor signaling and possible anti-fibrotic or vascular mechanisms 1, 2, 3. They do not establish a standard patient indication, a validated patient dose, or a reliable list of side effects in humans.

Animal and cell findings versus human outcomes

Animal and cell studies are useful early steps. But many compounds that look promising in models do not become safe, effective human therapies after full clinical testing.

That is why we separate mechanism from outcome. A peptide may change ERK1/2, cAMP, MMP-2, collagen, or vascular markers in a model, yet still fail to improve symptoms, organ function, or long-term health in people.

Why preclinical promise is not the same as proven safety or benefit

Safety is not only about the active peptide. It also depends on identity, purity, sterility, storage, dose, route of use, medical history, pregnancy status, kidney or liver disease, heart and blood pressure conditions, and drug interactions.

Why are B7-33 buying pages risky for patients?

B7-33 buying pages often blur the line between laboratory research and personal treatment. That matters because a vial sold online is not the same as a medication prescribed after a clinical review.

Research-use-only products are not the same as prescribed medication

FDA consumer guidance cautions patients to be careful with online drug sellers, especially when a seller does not require a prescription, has no licensed pharmacist available, or ships products of uncertain quality 6. For injectable or nasal products, quality concerns can be especially important because the route can bypass some normal body defenses.

Purity, sterility, storage, and identity concerns

For peptides, the label may not answer the most important questions: Is the compound what it says it is? Was it tested for sterility if intended for injection? Was it stored cold when needed? Does the vial contain contaminants or degradation products?

Why dose claims should be treated cautiously

Some online pages list B7-33 dose numbers. We do not provide personal dosing instructions for B7-33 because the published evidence does not establish a validated human regimen. Dose numbers from animal models or informal protocols should not be converted into self-treatment guidance.

When to talk with a licensed clinician instead of purchasing online

Talk with a licensed clinician before using any peptide for a health goal, especially if it is injectable, nasal, hormonal, cardiovascular, immune-related, or marketed for fibrosis, pregnancy-related conditions, sexual function, weight loss, or longevity.

Retatrutide is another example patients ask about. It is an investigational medication in clinical trials, not a treatment Chia offers, and we do not route patients to compounded retatrutide; patients should not treat online “retatrutide peptide” listings as routine prescription access 8.

Does Chia offer B7-33 or other peptide treatments?

Chia does not offer B7-33. We do offer several clinician-reviewed peptide and longevity options in our current public catalog, each requiring an online health questionnaire and licensed US provider review.

Chia does not offer B7-33

B7-33 is education-only for Chia readers. We do not sell it, prescribe it, or present it as a patient treatment.

Chia’s current clinician-reviewed peptide and longevity options

Chia’s current longevity and peptide-related options include Sermorelin, NAD+, Glutathione, GHK-Cu, PT-141, and Low-Dose Naltrexone. For patients who want a bundled longevity approach, our Foundation Longevity protocol includes Sermorelin Injection, NAD+ Injection, and Glutathione Injection.

How online evaluation, eligibility review, prescribing, and pharmacy shipping work at Chia

At Chia, care starts 100% online with a short health questionnaire. A licensed US provider reviews your information and prescribes only when clinically appropriate; a prescription is never guaranteed.

When treatment is prescribed, medications are compounded in the US by state-licensed 503A compounding pharmacies and shipped to your door. Dosing is provider-guided and adjusted over time, and patients can message their care team through the patient portal.

Where DoctorMCP may fit for agent-assisted prescription access

Some patients use AI agents to help organize prescription access. Where supported, Chia is reachable through DoctorMCP at mcp.chia.health for agent-assisted navigation, but the clinical standard does not change: treatment still requires a licensed provider’s evaluation and is never guaranteed.

How does B7-33 compare with peptide treatments that are available through Chia?

B7-33 is best understood as a research peptide, while Chia-offered options are clinician-reviewed treatments from our current catalog. This comparison is not a substitute recommendation; it is a practical way to separate access status, form, and evidence limits.

Sermorelin, NAD+, glutathione, GHK-Cu, PT-141, and low-dose naltrexone: what Chia offers and in what forms

The key difference is not that every Chia option has the same evidence base. They do not. The key difference is process: a licensed provider reviews eligibility, risks, route, medication history, and follow-up before prescribing.

Why this is not a substitute recommendation

Peptides are not interchangeable. A peptide studied for RXFP1 signaling is not a substitute for a growth-hormone secretagogue, a topical skin peptide, an antioxidant support therapy, or a sexual-health medication. The right next step depends on your goal and your medical history.

What should you ask before starting any peptide therapy?

Before starting peptide therapy, ask 4 basic questions: What human evidence exists, who is reviewing eligibility, where the product comes from, and what follow-up is included. These questions matter more than hype around any single molecule.

Is there human evidence for the intended use?

Ask whether the intended use is supported by human trials, observational human data, animal data, or cell data. For B7-33, the honest answer is that the main evidence is preclinical, not human outcome evidence 1, 2, 3.

Is a licensed clinician reviewing eligibility and risks?

A clinician should review pregnancy status when relevant, blood pressure, cardiovascular history, immune conditions, cancer history when relevant, allergies, current medications, and prior reactions to injections or nasal products.

Is the product coming from an appropriate pharmacy or only a research supplier?

For human medication use, the product should come through an appropriate medical channel, not a research-only seller. FDA guidance on compounding emphasizes that compounded drugs are not FDA-approved and are made for patients when certain legal conditions are met 7.

What monitoring and follow-up are included?

Follow-up matters because side effects can occur even with clinician-reviewed treatment. Depending on the therapy, follow-up may include symptom checks, dose adjustments by the provider, lab review, injection-site guidance, or stopping treatment if risks outweigh benefits.

FAQ

Keep reading

Longevity

Peptides for Longevity: What Human Evidence Actually Supports

Peptides

Do You Need a Prescription for BPC-157?

Peptides

Can You Buy Thymosin Alpha-1 Peptide? What Patients Should Know